文献速递骨软组织肉瘤与黑色素瘤

腺泡状软组织肉瘤的自然病程与治疗敏感性:法国肉瘤组全国多中心分析

Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group.
PubMed 文献 · Eur J Cancer · 2026-02-17

局限期患者均接受手术,5年OS率96.3%(95%CI 76.5-99.5%);转移后一线化疗、TKI和免疫治疗的客观缓解率分别为7%、26%和40%。

要点

  • ASPS整体预后较好,局限期患者5年OS率达96.3%。
  • 转移后一线免疫治疗客观缓解率40%,高于TKI的26%和化疗的7%。
  • 局限期患者半数出现转移复发,中位无转移生存87.9个月。

核心结论

  • ASPS在局限期和转移期均表现为较长生存,免疫治疗在系统治疗中客观缓解率最高。

主要发现

  • 全队列5年OS率为87.3%(95%CI 75.0-93.8%)。
  • 局限期患者中半数出现转移复发,中位无转移生存87.9个月(95%CI 29.6-NE)。
  • 转移患者一线系统治疗的客观缓解率:化疗7%、TKI 26%、免疫治疗40%。
  • 转移诊断后5年OS率为67.7%(95%CI 50.5-80.0%)。

临床怎么用

  • 局限期ASPS应接受手术,部分患者可联合围手术期放疗。
  • 转移性ASPS系统治疗中免疫治疗客观缓解率最高,TKI次之,化疗最低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alveolar soft part sarcoma (ASPS) is an ultra-rare sarcoma with limited chemotherapy sensitivity affecting mostly young patients. Tyrosine kinase inhibitors (TKIs) and immunotherapy are therapeutic advances with promising results in this disease. The aim of this study was to describe the characteristics, management and survival of patients with ASPS in France. PATIENTS AND METHODS: The French NETSARC+ database was screened for all adult patients with ASPS managed in French sarcoma centers between 2010 and 2023. RESULTS: Sixty-four patients from 18 centers were analyzed. The 5-year overall survival (OS) of the entire cohort was 87.3 % (95 % CI, 75.0-93.8 %). Fifty-six percent of patients had localized tumors at diagnosis; all were treated surgically, and 47 % received perioperative radiotherapy. With a median follow-up of 91 months, their 5-year OS was 96.3 % (95 % CI, 76.5-99.5 %). Half of the patients experienced metastatic recurrence with a median metastasis-free survival of 87.9 months (95 % CI, 29.6-NE). In patients with metastases, the first-line systemic treatment yielded an overall response rate of 7 %, 26 %, and 40 % for chemotherapy, TKIs, and immunotherapy, respectively. The 5-year OS after metastasis diagnosis was 67.7 % (95 % CI: 50.5-80.0 %). CONCLUSION: Our cohort reinforces existing data on clinical characteristics and demonstrated prolonged survival in both localized and metastatic stages. Among systemic treatments, immunotherapy achieved the highest response rates. We confirmed that ASPS may follow an indolent course in some cases and highlighted recent advances in its management, driven by standardized local treatments in reference centers and innovative systemic therapies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kalfala E, Meurgey A, Hénon C, et al. Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group. Eur J Cancer. 2026. PMID: 41719753. doi:10.1016/j.ejca.2026.116590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。